January 26, 2018

Venetoclax Active in CLL Progressing After Idelalisib

Venetoclax had promising clinical activity, with a high objective response rate among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with idelalisib, according […]
January 23, 2018

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients

 It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T-cell approach that is less toxic and does not require […]
December 12, 2017

Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma

Clinicians may soon have a valuable new therapeutic option for treating patients with cutaneous T-cell lymphoma (CTCL). Results of a randomized phase III study presented at […]
December 5, 2017

New Drug Target Discovered for Acute Myeloid Leukemia

 A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells 
August 18, 2017

FDA Approves New Acute Lymphoblastic Leukemia Treatment

The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]
June 28, 2017

Experimental FLT3 Inhibitor May Benefit Patients with Refractory AML

Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University […]